Xylometazoline
(Synonyms: Ba-11391, Otrivine, Rhinoxilin) 目录号 : GC26085Xylometazoline (Ba-11391, Otrivine, Rhinoxilin) is a nasal vasoconstricting decongestant drug which is used to improve symptoms of nasal congestion, allergic rhinitis, and sinusitis.
Cas No.:526-36-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Xylometazoline (Ba-11391, Otrivine, Rhinoxilin) is a nasal vasoconstricting decongestant drug which is used to improve symptoms of nasal congestion, allergic rhinitis, and sinusitis.
| Cas No. | 526-36-3 | SDF | Download SDF |
| 别名 | Ba-11391, Otrivine, Rhinoxilin | ||
| 分子式 | C16H24N2 | 分子量 | 244.38 |
| 溶解度 | DMSO: 49 mg/mL (200.51 mM);Water: Insoluble;Ethanol: 49 mg/mL (200.51 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.092 mL | 20.4599 mL | 40.9199 mL |
| 5 mM | 0.8184 mL | 4.092 mL | 8.184 mL |
| 10 mM | 0.4092 mL | 2.046 mL | 4.092 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Effects of intranasal Xylometazoline, alone or in combination with ipratropium, in patients with common cold
Curr Med Res Opin 2010 Apr;26(4):889-99.PMID:20151787DOI:10.1185/03007991003648015.
Background: Common cold is one of the most prevalent conditions that family doctors encounter. One of the first symptoms to occur is nasal congestion, which can have a negative impact on daily life and prompts many patients to seek treatment for relief. Xylometazoline nasal spray (Otrivin*) is a topical decongestant that has been used successfully for many years and is generally recognized as an effective and safe therapy. However, most studies have investigated its clinical efficacy in healthy patients and few have included patients with common cold. Scope: To review the published clinical efficacy and safety of Xylometazoline alone and in combination in the management of nasal congestion in patients with common cold. Literature searches of PubMed and the Cochrane Library were conducted to obtain published open or blinded, randomized, placebo- or active-controlled studies on the use of Xylometazoline hydrochloride for the symptomatic relief of nasal congestion in patients with common cold. Searches included papers published in English only, up to September 2009. Findings: Despite the small number of studies identified in common cold (n = 4), as per search criteria defined, intranasal Xylometazoline quickly and effectively relieved nasal congestion. When used alone, Xylometazoline had a clinically relevant decongestant effect that was significantly superior for up to 10 hours compared with placebo. The superior decongestant effect with Xylometazoline led to high patient satisfaction with treatment. When used in combination with ipratropium bromide, nasal congestion and rhinorrhoea were treated simultaneously, leading to significantly higher patient general impression scores compared with either agent used alone. Xylometazoline was well tolerated, with generally mild to moderate nasal-related side effects (e.g. epistaxis in 3.4% of patients, and blood-tinged mucus in 10-26% of patients) that were easily resolved; the most frequently reported non-nasal AEs were headache (3.4%) and period pain (10.3%); no cases of sedation were reported. As expected, no rhinitis medicamentosa or rebound congestion was noted with short-term use (<10 days). No clinically important differences in ciliary motility and mucociliary clearance were observed. Xylometazoline does not result in sympathomimetic systemic side effects seen with oral decongestants (e.g. pseudoephedrine, phenylephrine). Conclusions: The few studies available in common cold suggest that intranasal Xylometazoline provides fast and effective relief of nasal congestion and is well tolerated. When Xylometazoline is used in combination with ipratropium, patients with common cold experience the additive benefit of nasal congestion and rhinorrhoea being treated simultaneously.
Sinusitis (acute)
BMJ Clin Evid 2011 Dec 21;2011:0511.PMID:22189346doi
Introduction: Acute sinusitis is defined pathologically, by transient inflammation of the mucosal lining of the paranasal sinuses lasting less than 4 weeks. Clinically, it is characterised by nasal congestion, rhinorrhoea, facial pain, hyposmia, sneezing, and, if more severe, additional malaise and fever. It affects 1% to 5% of the adult population each year in Europe. Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments in people with clinically diagnosed acute sinusitis, and in people with radiologically or bacteriologically confirmed acute sinusitis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2011 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). Results: We found 19 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics (amoxicillin, amoxicillin-clavulanic acid [co-amoxiclav], doxycycline, cephalosporins, macrolides; different doses, long-course regimens), antihistamines, decongestants (Xylometazoline, phenylephrine, pseudoephedrine), saline nasal washes, steam inhalation, and topical corticosteroids (intranasal).
Efficacy and safety of intranasal Xylometazoline and ipratropium in patients with common cold
Expert Opin Pharmacother 2009 Apr;10(5):889-908.PMID:19351236DOI:10.1517/14656560902783051.
Background: Many over-the-counter medications are available to treat common cold nasal symptoms, but patients may be unsure which one to use. Methods: This review assesses two widely used intranasal treatments for nasal congestion and rhinorrhea in the common cold: Xylometazoline hydrochloride and ipratropium bromide. Results: Xylometazoline quickly and effectively relieves nasal congestion, while ipratropium is effective at reducing rhinorrhea. When used in combination, a novel approach to treatment, nasal congestion and rhinorrhea are treated simultaneously, providing effective relief from two of the most troublesome symptoms of the common cold Both drugs are well tolerated, with only mild to moderate, nasal-related side effects. Conclusions: The efficacy and safety of the combination product suggest that it should be used first-line in the symptomatic relief of nasal congestion and rhinorrhea, before the use of oral treatments.
Use of Xylometazoline in hospitalised infants: is it safe? A retrospective cohort study
Arch Dis Child 2023 Jan;108(1):62-66.PMID:36171065DOI:10.1136/archdischild-2022-324127.
Objective: When infants suffer from nasal congestion, Xylometazoline spray or drops can be effective to facilitate breathing and drinking. However, case reports on side effects have resulted in international warnings regarding use of Xylometazoline in infants. Nevertheless, the incidence of these side effects in hospitalised infants is unknown. Design: Retrospective cohort study. Setting: Teaching hospital between 2017 and 2021. Patients: Infants under 2 years of age. Exposure: Receiving either saline-only (unlimited frequency, concentration 0.9%) or in combination with Xylometazoline (maximum three times daily, concentration 0.025%). Main outcome measures: Predefined potential side effects (events), including among others apnoea, nausea, bradycardia, cyanosis and nosebleeds, were extracted from patient records, and the probability to be caused by saline only or xylometazoline-saline was determined using the ADR Probability Scale. Results: We included 898 admitted children during 1285 treatment episodes who received saline with or without Xylometazoline. 26 events occurred in the saline-only group (incidence 20.0/100 treatment episodes), and 117 events occurred in the Xylometazoline saline group (incidence of 10.5/100 treatment episodes), which was significantly lower (OR 0.47 95% CI 0.29 to 0.75, p=0.002). No definite linked or life-threatening events were found. Three nosebleeds had a probable link to the use of xylometazoline-saline, and all other events could only possibly be linked to saline-only or Xylometazoline saline use. The incidence of all events was higher in the saline-only group as compared with the Xylometazoline saline group, except nausea, which had a similar occurrence (p=0.65). Results were very similar across (gestational) age groups, gender and reasons for admission. Conclusion: The use of low-dose Xylometazoline seems to be safe in hospitalised infants.
Topical nasal Xylometazoline for flexible bronchoscopy (VAIN): A randomized, double-blind, placebo-controlled trial
Respir Investig 2021 May;59(3):350-355.PMID:33518471DOI:10.1016/j.resinv.2020.12.004.
Background: The role of topical nasal vasoconstrictor administration during flexible bronchoscopy is unclear. Methods: Consecutive subjects undergoing flexible bronchoscopy were randomized to receive either topical Xylometazoline (0.1%) or placebo (saline nasal spray, 0.74% w/v isotonic solution) before bronchoscopy. Background topical anesthesia included 2% nasal lignocaine gel, pharyngeal spray of 10% lignocaine, and 1% lignocaine solution for spray-as-you-go administration. The primary outcome was the operator rated ease of nasal negotiation of the bronchoscope on the visual analog scale (Negotiation VAS). Secondary objectives included assistant rated facial pain scale score, patient-rated nasal pain score (Pain VAS), time to reach the vocal cords after bronchoscope insertion, operator rated nasal mucosal trauma score (Trauma VAS), hemodynamic changes, and complications between the groups. Results: In all, 148 subjects were recruited and randomized to the placebo (73) and Xylometazoline groups (75). Operator rated ease of nasal bronchoscope negotiation (Negotiation VAS) was similar in both the groups [Median (IQR), 1 (1-2) in both groups, p = 0.79]. There were no differences in the other outcomes including assistant rated score of facial pain [(Median (IQR), 2 (2-4) placebo and 2 (2-4) Xylometazoline, p = 0.36], Pain VAS [Median (IQR), placebo 2 (1-2) and Xylometazoline 2 (1-3), p = 0.28], Trauma VAS, [Median (IQR), placebo 1 (0-2) and Xylometazoline 1 (0-1), p = 0.28], hemodynamic changes, or complications between the two groups. Conclusion: The findings of this study do not support the administration of topical nasal Xylometazoline in flexible bronchoscopy. Trial registry: Trial registered on Clinicaltrials.gov, www.clinicaltrials.govNCT03424889, on January 02, 2018.